(Q46764241)

25 December 2017

title

Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties (English)

1 reference

25 December 2017

author

Adrian Newman-Tancredi

5

1 reference

25 December 2017

author name string

Laurent Bardin

1

1 reference

25 December 2017

Mark S Kleven

2

1 reference

25 December 2017

Catherine Barret-Grévoz

3

1 reference

25 December 2017

Ronan Depoortère

4

1 reference

25 December 2017

language of work or name

English

0 references

publication date

19 October 2005

1 reference

25 December 2017

published in

Neuropsychopharmacology

1 reference

25 December 2017

volume

31

1 reference

25 December 2017

issue

9

1 reference

25 December 2017

page(s)

1869-1879

1 reference

25 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.npp.1300940

exact match

0 references

cites work

SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

5-HT1A receptor agonist properties of the antipsychotic, nemonapride: comparison with bromerguride and clozapine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Is there a role for 5-HT1A agonists in the treatment of depression?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

New Insights into the Biology of Schizophrenia through the Mechanism of Action of Clozapine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Relationship of the use of adjunctive pharmacological agents to symptoms and level of function in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Reversal of haloperidol-induced extrapyramidal side effects in cebus monkeys by 8-hydroxy-2-(di-n-propylamino)tetralin and its enantiomers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Stimulation by antipsychotic agents of mitogen-activated protein kinase (MAPK) coupled to cloned, human (h)serotonin (5-HT)(1A) receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

An observational method for quantifying the behavioural effects of dopamine agonists: Contrasting effects of d-Amphetamine and apomorphine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Role of 5-HT1A receptors in the ability of mixed 5-HT1A receptor agonist/dopamine D2 receptor antagonists to inhibit methylphenidate-induced behaviors in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Serotonin receptors: their key role in drugs to treat schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Acute exacerbation of psychosis with buspirone?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Effects of dopamine antagonists in a two-way active avoidance procedure in rats: interactions with 8-OH-DPAT, ritanserin, and prazosin.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

The cataleptogenic effects of the neuroleptic nemonapride are attenuated by its 5-HT1A receptor agonist properties

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Interactions between neuroleptics and 5-HT(1A) ligands in preclinical behavioral models for antipsychotic and extrapyramidal effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Effects of WAY 100635 on antipsychotic-induced catalepsy in 5-HT depleted animals: a role for tonic activation of 5-HT(1A) receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Development of 5-HT1A receptor antagonists

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Effect of tandospirone on tardive dyskinesia and parkinsonian symptoms.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300940

7 January 2021

Identifiers

DOI

10.1038/SJ.NPP.1300940

1 reference

25 December 2017

1 reference

25 December 2017